Abstract
The objective of this prospective multicenterstudy was to determine whether cisapride is associatedwith increased risk of malformations, spontaneousabortions, or decreased birthweight when used during pregnancy. Cases were paired for age, smoking,and alcohol consumption with controls exposed tononteratogens, as well as with disease-paired controls.One hundred and twenty-nine pregnant women were exposed to cisapride during pregnancy, including 88during the period of fetal organogenesis. There were nodifferences in maternal history, birthweight,gestational age at delivery, and rates of livebirths,spontaneous or therapeutic abortions, fetal distress, andmajor or minor malformations among groups. It isconcluded that exposure to cisapride during pregnancy isnot associated with a major increased risk ofmalformations or spontaneous abortions or with decreasedbirthweight.
Similar content being viewed by others
REFERENCES
Barone JA, Jessen LM, Colaizzi JI, Bierman RH: Cisapride: A gastrointestinal prokinetic drug. Ann Pharmacother 28:488–500, 1994
Bruton LL: Agents affecting gastrointestinal water flux and motility; Emesis and antiemetics; bile acids and pancreatic enzymes. In Goodman and Gilman's The Pharmacological Basis of Therapeutics. JG Hardman, LE Limbird, PB Molinoff, RW Ruddon, AG Gilman (eds). New York, McGraw-Hill, 1996, p 933
McCallum RW: Cisapride: A new class of prokinetic agent. Am J Gastroenterol 86:135–149, 1991
Bennett JR: How safe and acceptable is cisapride? Scand J Gastroenterol 24:59–61, 1989
Van Neuten JM, Van Daele PGH, Reyntjens AJ, Janssen PAJ, Schuurkes JAJ: Gastrointestinal motility stimulating properties of cisapride, a non-antidopaminergic non-cholinergic compound. In Gastrointestinal Motility: C Roman (ed). Hingham, MTP Press, 1984, pp 513–520
Schuurkes JAJ, Van Nueten JM, Van Daele PGH, Reyntjens AJ, Janssen PAJ: Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J Pharmacol Exp Ther 234:775–783, 1985
Everson GT: Gastrointestinal motility in pregnancy. Gastroenterol Clin North Am 21:751–776, 1992
Simone C, Derewlany LO, Koren G: Drug transfer across the placenta. Considerations in treatment and research. Clin Perinatol 21:463–468, 1994
Pelligrini EM, Koren G: Motherisk I: A new model for counseling in reproductive toxicology. In Maternal-Fetal Toxicology: A Clinician's Guide. G Koren (ed). New York, Dekker, 1994, pp 707–725
Stevenson RE: Causes of human anomalies: An overview and historical perspective. In Human Malformations and Related Anomalies, Vol 1. RE Stevenson (ed). New York, Oxford University Press, 1993, pp 3–20
Moore KL: The Developing Human. Philadelphia, WB Saunders, 1988
Abacus Concepts: Statview SE + Graphics™, 1988
Skrabanek P: Smoking and statistical overkill. Lancet 340:1208–1209, 1992
Veereman-Wauters G, Monbaliu J, Meuldermans W, Woesterborghs R, Verlinden M, Heykants J, Rudolph CD: Study of the placental transfer of cisapride in the sheep. Plasma levels in the pregnant ewe, the fetus, and the lamb. Drug Metab Disp 19:168–172, 1991
United States Pharmacopeial Convention Inc: Cisapride. In USP Dispensing Information Volume I: Drug Information for the Health Care Professional, 16th ed. Massachusetts, Rand McNally, 1996, pp 849–850
Magee LA, Inocencion G, Kamboj L, Rosetti F, Koren G: Safety of first trimester exposure to histamine H2 blockers: A prospective cohort study. Dig Dis Sci 41:1145–1149, 1996
Schardein JL: Chemically Induced Birth Defects. New York, Marcel Dekker, 1985, pp 452–466
Rights and permissions
About this article
Cite this article
Bailey, B., Addis, A., Lee, A. et al. Cisapride Use During Human Pregnancy (A Prospective, Controlled Multicenter Study). Dig Dis Sci 42, 1848–1852 (1997). https://doi.org/10.1023/A:1018898707449
Issue Date:
DOI: https://doi.org/10.1023/A:1018898707449